John Theurer Cancer Center First NJ Site Certified to Offer CAR-T Cell Cancer Therapy

John Theurer Cancer Center is among limited U.S. sites, and the only hospital in New Jersey certified to offer Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded or who have relapsed after at least two other kinds of treatment. “John Theurer Cancer Center has been involved in CAR-T cell therapy research for nearly a decade,” said Andre Goy, M.D., chairman and executive director of the John Theurer Cancer Center, chief of the Lymphoma Division, professor of medicine at Georgetown University. Dr. Goy co-authored the study, Axicagagene Ciloleucel (CD19 CAR T) in Refractory Large B-Cell Lymphoma, presented at the 59th Annual Meeting of the American Society of Hematology and published on December 10, 2017 in the New England Journal of Medicine. “This new therapeutic modality represents the first gene modified cell based live therapy approved for adults, and will radically change the paradigm in several subtypes of hematological malignancies or blood cancers.” (This story was also featured in Commerce Magazine.)

Read full article on